<DOC>
	<DOCNO>NCT00664170</DOCNO>
	<brief_summary>The purpose study compare injectable emulsion form docetaxel Taxotere patient advance cancer .</brief_summary>
	<brief_title>A Bioequivalence Study Docetaxel Injectable Emulsion ( ANX-514 ) Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Over 18 year old . Advanced cancer potentially sensitive single agent docetaxel ; ie.. locally advanced metastatic breast cancer , locally advance nonsmall cell lung cancer , hormone refractory metastatic prostate cancer , tumor type standard treatment . ECOG performance status 02 Karnofsky Score 10070 . Patients effective therapy available single agent docetaxel malignancy . Pregnancy lactation . Intolerance antineoplastic agent belong taxoid family . Hypersensitivity drug formulate polysorbate 80 . Active infection . Prior anticancer therapy within 30 day prior first day study treatment . Participation another experimental drug study within 30 day prior first day study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>